.jpg "Ironwood Pharma (NASDAQ: IRWD)")
In a report released today, Boris Peaker from Cowen & Co. maintained a Hold rating on Ironwood Pharma (IRWD), with a price target of $12. The company’s shares closed yesterday at $10.60.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.5% and a 41.1% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Ironwood Pharma has an analyst consensus of Hold, with a price target consensus of $13.60, which is a 28.3% upside from current levels. In a report issued on July 10, Credit Suisse also initiated coverage with a Hold rating on the stock.
See today’s analyst top recommended stocks >>
Based on Ironwood Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $59.28 million. In comparison, last year the company had a GAAP net loss of $49.38 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonist which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F.
